Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

BioMar - Presentation of the Q3 2026 Interim Report

BIOMAR03.11.2026, 14.00
HC Andersen Capital

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

BioMar is expected to release its interim report for the first nine months of 2026 on 3 November 2026. The same day at 14:00 CET, BioMar's CEO, Carlos Diaz, will present the results and answer questions from the audience in a live online event.

In Q2 2026, BioMar delivered record feed volumes of 395,000 tonnes, up 3% year on year, and revenue of DKK 4,164m, up 5%. EBIT declined 3% to DKK 250m with a margin of 6.0%, reflecting higher raw material prices, the planned transformation in Tech Solutions and IPO costs, while underlying feed EBIT grew 7%.

On the back of the report, management raised full-year guidance to volumes of 1,630-1,700 thousand tonnes, revenue of DKK 17.0-18.0 billion and EBIT of DKK 1,200-1,300m, with CAPEX of DKK 400-500m.

Measured against 2025, the raised guidance implies volume growth of 5-9%, revenue growth of 3-9% and EBIT growth of 6-15%, with an implied EBIT margin of 6.7-7.6% versus 6.8% in 2025. Over the medium term towards 2030, BioMar targets average annual volume growth of 4-6%, EBIT growth of 8-10%, ROIC above 20% and a dividend payout of at least 50% of net profit.

Focus besides the financial results is likely to centre on the commissioning of the first phase of the Ecuador expansion, around 110,000 tonnes of capacity expected at the end of the year, salmon volumes and biological conditions in Norway and Chile, the normalisation of Tech Solutions, and BioMar's ability to pass through rising marine raw material prices, and whether the raised full-year guidance leaves room for further upside.

Disclaimer: HC Andersen Capital receives payment from BioMar for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 13.03 08/10-2026.

Registrér dig til eventet

Kommende selskabspræsentationer

Seneste videoer

Keo Capital, Investor Update 2026
08.10.2026, 16.00 Keo Capital
Faron Pharmaceuticals, R&D day 2026
08.10.2026, 14.00 Faron Pharmaceuticals
HCA Morgenbørs 08/10 - Fokus på renter i interview med cheføkonom Søren Kristensen fra AL Sydbank
08.10.2026, 09.55 GreenMobility
Admicom, Webcast, Q3'26
08.10.2026, 09.00 Admicom
HCA Morgenbørs 07/10 - Fokus på Trophy Games i interview med CEO Søren Gleie
07.10.2026, 09.29 D/S Norden
Vis alle videoer